首页> 外文期刊>European journal of ophthalmology >One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma
【24h】

One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma

机译:为期一天的基于LINAC的后葡萄膜黑色素瘤立体定向放射外科手术

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose. LINAC-based stereotactic radiosurgery (SRS) of posterior uveal melanoma is a conservative method to treat uveal melanoma.Methods. This was a retrospective clinic-based study of patients with posterior uveal melanoma in stage T2/T3 who underwent 1-day session SRS at LIN AC accelerator or SRS plus combined methods from 2001 to 2008.Results. Thirty-nine patients with posterior uveal melanoma were treated with SRS (age 25-80 years, median 54 years). Median tumor volume at baseline was 0.6 cm3 (range 0.2-1.3 cm3). The therapeutic dose (TD) was 35.0 Gy, median of maximal dose applied was 49.0 Gy (range 37.0-60.0 Gy). Patient data were analyzed in groups: group 1, single SRS irradiation; group 2, SRS with subsequent endoresection or cyclectomy or additional transpupillary thermotherapy (TTT) or brachytherapy by Ru106 plaques; group 3a, enucleation after single SRS; group 3b, enucleation after SRS and endoresection/cyclectomy or TTT or brachytherapy Ru106. In patients with visual acuity of 20/40 or better, the median rate of best-corrected visual acuity (BCVA) decline was higher than that of the total and significantly higher than the rate of decline in the complementary group of patients with BCVA less than 20/40 (p=0.0077; Mann-Whitney U test).Conclusions. One-step LINAC-based SRS with a single dose 35.0 Gy is a method to treat middle-stage posterior uveal melanoma and to preserve the eye globe or as the first step of combined methods: irradiation before endoresection or cyclectomy.
机译:目的。基于LINAC的后葡萄膜黑色素瘤立体定向放射外科(SRS)是治疗葡萄膜黑色素瘤的保守方法。这是一项基于临床回顾性研究,研究对象为2001年至2008年在LIN AC加速器或SRS联合治疗下进行了为期1天SRS的T2 / T3期葡萄膜后黑色素瘤患者。对39例葡萄膜后叶黑色素瘤患者进行了SRS治疗(年龄25-80岁,中位年龄54岁)。基线时肿瘤中位数为0.6 cm3(范围为0.2-1.3 cm3)。治疗剂量(TD)为35.0 Gy,施加的最大剂量中位数为49.0 Gy(范围37.0-60.0 Gy)。分组分析患者数据:第1组,单次SRS照射;第2组,SRS,随后进行内膜切除或环切术或通过Ru106斑块进行额外的经瞳孔热疗(TTT)或近距离放射治疗; 3a组,单次SRS后摘除; 3b组,SRS和内镜切除/环切术或TTT或近距离放射治疗后摘除Ru106。在视敏度为20/40或更高的患者中,最佳矫正视敏度(BCVA)下降的中位数率高于总体,并且显着高于补充组BCVA小于20/40(p = 0.0077; Mann-Whitney U检验)。结论。单剂量35.0 Gy的基于LINAC的单步SRS是一种治疗中段后葡萄膜黑色素瘤并保护眼球的方法,或作为联合方法的第一步:在内镜切除术或环切术前进行放射治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号